ODN 1826

ODN 1826 is a class B CpG ODN (oligodeoxynucleotide) and TLR9 agonist. ODN 1826 induces NO and iNOS production and enhances Apoptosis. ODN 1826 enhances immune surveillance. ODN 1826 increases aortic atherosclerotic plaque size. ODN 1826 has antitumor activity against lung cancer, glioma and melanoma[1][2][3][4][5][6].

Product Specifications

CAS Number

[202668-42-6]

Product Name Alternative

CpG 1826

UNSPSC

12352208

Target

Apoptosis; NO Synthase; Toll-like Receptor (TLR)

Type

Oligonucleotides

Related Pathways

Apoptosis; Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Inflammation/Immunology; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/odn-1826.html

Purity

99.76

Solubility

H2O : 50 mg/mL (ultrasonic)

Smiles

[ODN1826]

Molecular Weight

6364.10

References & Citations

[1]Hou Y, et al. Lipoamide Ameliorates Oxidative Stress via Induction of Nrf2/ARE Signaling Pathway in PC12 Cells. J Agric Food Chem. 2019 Jul 24;67 (29) :8227-8234.|[2]Qi XF, et al. CpG oligodeoxynucleotide induces apoptosis and cell cycle arrest in A20 lymphoma cells via TLR9-mediated pathways. Mol Immunol. 2013 Jul;54 (3-4) :327-37. |[3]Utaisincharoen P, et al. CpG ODN activates NO and iNOS production in mouse macrophage cell line (RAW 264.7) . Clin Exp Immunol. 2002 Jun;128 (3) :467-73.|[4]Jordan M, et al. CpG-1826 immunotherapy potentiates chemotherapeutic and anti-tumor immune responses to metronomic cyclophosphamide in a preclinical glioma model. Cancer Lett. 2016 Apr 1;373 (1) :88-96.|[5]Krogmann AO, et al. Proinflammatory Stimulation of Toll-Like Receptor 9 with High Dose CpG ODN 1826 Impairs Endothelial Regeneration and Promotes Atherosclerosis in Mice. PLoS One. 2016 Jan 11;11 (1) :e0146326. |[6]Yuan S, et al. CpG oligodeoxynucleotide 1826 enhances the Lewis lung cancer response to radiotherapy in murine tumor. Cancer Biother Radiopharm. 2011 Apr;26 (2) :203-8.